Literature DB >> 3024076

Phosphatidylinositol turnover in neuroblastoma cells: regulation by bradykinin, acetylcholine, but not mu- and delta-opioid receptors.

V C Yu, W Sadée.   

Abstract

The effect of opioids on phosphatidylinositol (PI) turnover to release inositol triphosphate (IP3) as second messenger was examined in mouse neuroblastoma X rat glioma hybrid cells NG108-15 (delta-receptors) and human neuroblastoma cells, SK-N-SH (predominantly mu-receptors). PI turnover can be stimulated in both NG108-15 and SK-N-SH cells by bradykinin and acetylcholine, respectively. In contrast, etorphine, DADL ([D-Ala2,D-Leu5]-enkephalin) and DAGO ([D-Ala2,MePhe4,Gly-ol5]-enkephalin), up to 1 microM concentrations failed to affect PI turnover in both cell lines. These results suggest that IP3 is not likely to serve as second messenger for both mu- and delta-opioid receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3024076     DOI: 10.1016/0304-3940(86)90562-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  4 in total

1.  Dual signal transduction through delta opioid receptors in a transfected human T-cell line.

Authors:  B M Sharp; N A Shahabi; W Heagy; K McAllen; M Bell; C Huntoon; D J McKean
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

2.  Muscarinic receptors coupled to phosphoinositide hydrolysis and elevated cytosolic calcium in a human neuroblastoma cell line SK-N-SH.

Authors:  J G Baird; D G Lambert; J McBain; S R Nahorski
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

3.  Muscarinic receptor-mediated increase in zeta-PKC expression in SK-N-SH human neuroblastoma cells.

Authors:  J Baumgold; K D Dyer
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

4.  Quantitative comparisons of muscarinic and bradykinin receptor-mediated Ins (1,4,5)P3 accumulation and Ca2+ signalling in human neuroblastoma cells.

Authors:  G B Willars; S R Nahorski
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.